Feb 29, 2024 ACIP Meeting - Welcome & RSV Vaccines

Manufacturer presentation: Moderna safety & efficacy in adults aged ≥60 years; Risk-stratified rates of RSV-associated hospitalization among adults; Implementation update: older adult RSV vaccination; Post-marketing safety surveillance of older adult RSV vaccination; Preliminary Analysis of Guillain-Barré Syndrome (GBS) following RSV Vaccination among adults 65 years and older; Older adult RSV vaccination: benefits and risks discussion; Work group interpretations and discussion;

This video can also be viewed at
https://www.cdc.gov/vaccines/videos/low-res/ACIPFeb2024/ACIP-7_Welcome-RSV_02-29-2024_LowRes.mp4